Effectiveness and Safety of Adalimumab Biosimilar SB5 in IBD: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naieve SB5 Observational Cohorts.
Lauranne A A P DerikxHeather W DolbyNikolas PlevrisLaura A LucaciuCaitlin S ReesMathew LyonsSpyros I SiakavellasNathan Constantine-CookePhilip JenkinsonShanna SuClaire O'HareLaura KirckpatrickLynne M MerchantColin NobleIan D ArnottGareth-Rhys JonesCharlie W LeesPublished in: Journal of Crohn's & colitis (2021)
Switching from ADA originator to SB5 appeared effective and safe in this study with over 12 months of follow-up.